ArticleJournal for immunotherapy of cancer2024

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.

Sophia Frentzas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.